Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.33 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HMGCR | P04035 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Edetic Acid SCHEMBL749833 | 0.88 | TDP1 (0.47) | TDP1TSHRCYP2C19LMNAKDM4E | |
| SCHEMBL9372723 | 0.69 | TDP1 (0.46) | TDP1CYP2D6TSHRCYP2C19HIF1A | |
| SCHEMBL10520915 | 0.67 | TDP1 (0.43) | TDP1CYP2D6TSHRCYP2C19HIF1A | |
| SCHEMBL9474321 | 0.67 | TDP1 (0.43) | TDP1CYP2D6TSHRCYP2C19HIF1A | |
| SCHEMBL6230622 | 0.65 | TDP1 (0.37) | TDP1CYP2D6TSHRCYP2C19HIF1A | |
| Ammonia Solution, Strong SCHEMBL11416138 | 0.65 | LMNA (0.43) | TDP1CYP2D6TSHRCYP2C19GABRR1 | |
| SCHEMBL9618693 | 0.65 | TDP1 (0.37) | TDP1CYP2D6TSHRCYP2C19HIF1A | |
| Ammonia Solution, Strong SCHEMBL10537977 | 0.64 | TDP1 (0.41) | TDP1GABRR1SLC22A6LMNAKDM4E | |
| SCHEMBL10902910 | 0.64 | TDP1 (0.40) | TDP1CYP2D6TSHRCYP2C19HIF1A | |
| SCHEMBL13469352 | 0.62 | TDP1 (0.39) | TDP1CYP2D6TSHRCYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10196412-B2 | Probe for imaging PARP-1 activity | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-02-05 | — | — | US | claimed |
| US-20160185805-A1 | PROBE FOR IMAGING PARP-1 ACTIVITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2016-06-30 | — | — | US | claimed |
| EP-1420831-A1 | LIPID CONSTRUCTS AS THERAPEUTIC AND IMAGING AGENTS | Targesome, Inc. (US) | 2004-05-26 | — | — | EP | claimed |
| US-20030082103-A1 | Targeted therapeutic lipid constructs having cell surface targets | TARGESOME, INC. | 2003-05-01 | — | — | US | claimed |
| WO-2003028643-A2 | TARGETED THERAPEUTIC LIPID CONSTRUCTS HAVING CELL SURFACE TARGETS | TARGESOME, INC. (US) | 2003-04-10 | — | — | WO | claimed |
| WO-2003011345-A1 | LIPID CONSTRUCTS AS THERAPEUTIC AND IMAGING AGENTS | TARGESOME, INC. (US) | 2003-02-13 | — | — | WO | claimed |
| US-10196412-B2 | Probe for imaging PARP-1 activity | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-02-05 | — | — | US | disclosed |
| US-20160185805-A1 | PROBE FOR IMAGING PARP-1 ACTIVITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2016-06-30 | — | — | US | disclosed |
| EP-2396333-B1 | TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | ASTRAZENECA AB (SE) | 2013-07-03 | — | — | EP | disclosed |
| EP-2396333-A1 | TRIAZOLO [4,3-B]PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | AstraZeneca AB (SE) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010131022-A1 | [1,2,4] TRIAZOLO [4,3-B] PYRIDAZINES AS LIGANDS OF THE ANDROGEN RECEPTOR | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| EP-1928861-B1 | 4- (IH-INDAZOL-5-YL-AMINO)-QUINAZOLINE COMPOUNDS AS ERBB RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2010-11-17 | — | — | EP | disclosed |
| US-20100278846-A1 | NASAL-ADMINISTERED VACCINES USING MULTI-SCREENED NALT-TARGETING AND PHAGOCYTIC POLYPEPTIDE TRANSPORT SEQUENCES | FERGUSON IAN A | 2010-11-04 | — | — | US | disclosed |
| EP-1420831-A1 | LIPID CONSTRUCTS AS THERAPEUTIC AND IMAGING AGENTS | Targesome, Inc. (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20040067196-A1 | Targeted therapeutic lipid constructs | TARGESOME INC | 2004-04-08 | — | — | US | disclosed |
| US-20030082103-A1 | Targeted therapeutic lipid constructs having cell surface targets | TARGESOME, INC. | 2003-05-01 | — | — | US | disclosed |
| WO-2003028643-A2 | TARGETED THERAPEUTIC LIPID CONSTRUCTS HAVING CELL SURFACE TARGETS | TARGESOME, INC. (US) | 2003-04-10 | — | — | WO | disclosed |
| WO-2003011345-A1 | LIPID CONSTRUCTS AS THERAPEUTIC AND IMAGING AGENTS | TARGESOME, INC. (US) | 2003-02-13 | — | — | WO | disclosed |
| US-4920061-A | SPHERICAL PARAMAGNETIC COBALT PARTICLES HAVING AFFINITY LIGANDS ADSORBED ON SURFACES | THE UNIVERSITY OF TEXAS SYSTEM (US) | 1990-04-24 | — | — | US | disclosed |
| US-4164477-A | ACIDS, SULFONATES, POLYESTERS OR ETHYLENE OXIDE ADDUCTS, OXY AMINES OR OXY AMIDES, ALKYD RESINS | Chem-X3, Inc. (US) | 1979-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196412-B2 | Probe for imaging PARP-1 activity | PARP1, PARP2, PARP12 | TDP1 117/4885CYP2D6 1519/4885TSHR 2609/4885 |
| US-20160185805-A1 | PROBE FOR IMAGING PARP-1 ACTIVITY | PARP1, PARP2, PARP12 | TDP1 117/4885CYP2D6 1519/4885TSHR 2609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.